Patients who have received transplants generally require life-long immunosuppressive drugs, which are all associated with potentially life- threatening adverse effects. Occasionally, "tolerant" patients have been able to stop these drugs without losing their grafts, but we cannot differentiate them from others in whom stopping these drugs will result in rejection. In this project, specimens will be collected from tolerant patients and used in a series of novel, tests of immunological reactivity which have been developed by the consortium. An adequate number of such rare patients could only be collected from within a very large population, necessitating a collaboration of this size. We predict that this will reveal a tolerant "fingerprint' which can then be used to identify those whose drugs can be stopped and to define drug protocols which can induce tolerance.
Funding SchemeDEM - Demonstration contracts
OX3 9DU Oxford